Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review

Shunan Wang¹
Wei Guo¹
Xin Wan¹
Yongliang Teng²
Xiaoge Zhou³
Ou Bai¹

¹Department of Hematology, The First Hospital of Jilin University, Changchun, ²Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China

Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy mainly affecting elderly patients. It is highly responsive to chemotherapy, but the median event-free survival is very short and has a high rate of relapse even after performing allogeneic stem cell transplantation; thus, the discovery of novel agents for the treatment of BPDCN is urgent. Chidamide is a new oral isotype-selective histone deacetylase inhibitor (HDACi). It is proved to exert a well-characterized anticancer property in a wide range of hematological malignancies, especially lymphoma. Here, we report a 41-year-old man who used oral chidamide 30 mg twice per week for maintenance therapy after receiving complete remission. For the first time in this field, we had explored the efficiency of chidamide in the treatment of BPDCN and tried to give more choices to the therapy of this disease.

Keywords: hematopoietic malignancy, skin lesions, maintenance therapy, histone deacetylase inhibitor

Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy derived from precursor plasmacytoid dendritic cells. It was classified as a distinct entity among myeloid neoplasms in the 2016 WHO classification.¹ It mainly affects older individuals with a median age of 60–70 years and has an obvious male predominance. Most patients present with asymptomatic skin lesions as the first symptom and have a high frequency of bone marrow involvement. BPDCN is typically characterized by CD4⁺ and CD56⁺ co-expression without common lymphoid or myeloid lineage markers. Accounting for only 0.44% of all hematological malignancies, the standard and definitive systemic chemotherapy regimen of BPDCN is difficult to establish.² The prognosis of this disease is very poor with a mean survival of 12–14 months.³ Thus, it is urgent to illuminate the pathobiology of BPDCN and utilize novel agents in this disease. Chidamide is a new oral isotype-selective histone deacetylase inhibitor (HDACi) that has been proved to be effective in a wide range of hematological malignancies and has been approved in China for the treatment of recurrent or refractory peripheral T-cell lymphoma (PTCL).

In this study, we present the case of a BPDCN patient who underwent central nervous system (CNS) involvement soon after the first complete remission (CR). In the second CR, novel regimen chidamide was chosen to maintain the therapeutic effect. This is the first case of BPDCN treated with chidamide, giving more choice to the clinical application of chidamide.
Case presentation

Diagnosis

Written informed consent was obtained from the patient’s next of kin for publication of this case report and the associated images. A 41-year-old man presenting with an 8-day history of left inguinal lymph node enlargement came to the hospital for evaluation. A physical examination showed palpable left inguinal lymph node measuring 2–4 cm; no skin lesions were identified. The inguinal lymph node biopsy showed effacement of normal nodal architecture by diffuse proliferation of homogeneous midsized lymphoid cells with ovoid or pleomorphic nuclei, small or inconspicuous nucleoli, hypochromic chromatin and red blood cells and small lymphocytes dispersed within them (Figure 1A). Immunohistochemical analysis showed that the neoplastic cells were positive for CD43, indicating hematopoietic malignancy, and were specifically positive for CD123, CD4 and CD56 (Figure 1B–D) but negative for all other markers examined, including T-cell (CD3, CD2, CD5, CD8), B-cell (CD20, CD79a), myeloid- or monocytic-associated (MPO, CD34) markers. Hence, the pathological diagnosis of BPDCN was made. Ki-67 was positive in ~30%–40% of atypical cells.

Bone marrow smear, immunohistochemical analysis of bone marrow biopsy and flow cytometric analysis of bone marrow fluid indicated the involvement of bone marrow. Karyotype analysis revealed chromosomal abnormalities, including 46,XY,t(9;17)(q34;q21) and 46,XY,inv(17) (q21q23). In situ hybridization for the Epstein–Barr virus genome, T-cell gene rearrangement studies and genotyping detection showed no abnormality. With no skin lesions or abnormality on blood cell count, the patient refused immediate therapy.

After 5 months, with progressive diffuse lymphadenopathy, facial skin lesions (Figure 2A), conjunctival congestion and dyspnea on exertion, the patient returned to the hospital for further treatment. Bone marrow smear was performed again, and the specimen demonstrated diffuse infiltration of lymphoblast and prolymphocyte, accounting for 58.5% compared with 15.5% last time. Fluorodeoxyglucose positron emission tomography/computed tomography imaging revealed markedly increased fluorodeoxyglucose-avid region in diffuse swollen lymph nodes, enlarged spleen and the whole skeleton. The involvement of diffuse lymph nodes, spleen, skin and bone marrow was confirmed.

This report involves a case of BPDCN with a young patient who presented with specifically facial skin lesions, and the disease was extensively invasive and progressing rapidly.

Figure 1 The results of swollen lymph node biopsy section.

Notes: (A) Diffuse proliferation of homogeneous midsized lymphoid cells with ovoid or pleomorphic nuclei, small or inconspicuous nucleoli and hypochromic chromatin (×400). (B) CD123 positive for neoplasm cells (×400). (C) CD4 positive for neoplasm cells (×400). (D) CD56 positive for neoplasm cells (×400).
The patient was highly responsive to acute lymphoblastic leukemia (ALL)-like regimens but the involvement of the CNS occurred soon, indicating the importance of CNS prophylaxis. However, regimens used in relapsed/refractory ALL were still effective.

The possible reasons of CNS relapse are as follows: First, CNS involvement occurs in 10% of all patients with BPDCN at diagnosis and in 30% of relapsed patients, so the detection of cerebrospinal fluid is crucial to increase the accuracy rate of the diagnosis and the prophylactic intrathecal therapy at the very beginning may help to prevent the CNS relapse. Second, bone marrow involvement was presented in this patient at diagnosis, which indicated that the patient was seriously ill and the disease was highly aggressive with a high rate of relapse. Third, the patient did not receive therapy immediately, and a 5-month delay gave the opportunity for rapid deterioration of the disease.

### Maintenance therapy

Being tired of chemotherapy and wishing for improvement in the quality of life, the patient refused chemotherapy demanding intravenous instillation and chose to prevent disease relapse with oral anticancer medicine, which was well tolerated and effective. After cautious discussion and repeated communication with the patient, a novel regimen involving chidamide was chosen ultimately, and it was taken orally 30 mg twice per week (biw) to prevent the relapse. Blood cell count and biochemical index were tested regularly to monitor the side effects. Chidamide appeared to be well tolerated, and only thrombocytopenia (grade 2) occurred but the platelet levels recovered soon after transitory drug withdrawal.

### Table 1 Inductive and consolidative therapy

<table>
<thead>
<tr>
<th>No</th>
<th>Regimen</th>
<th>Dose</th>
<th>Course</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>VDCP</td>
<td>CTX 1,200 mg/m² day 1; VDS 4 mg days 1, 8, 15, 22; DNR 45 mg/m² days 1–3; PDN 60 mg/m² days 1–21</td>
<td>1</td>
<td>PR</td>
</tr>
<tr>
<td>2</td>
<td>VDCP</td>
<td>CTX 1,200 mg/m² day 1; VDS 4 mg days 1, 8, 15, 22; DNR 45 mg/m² days 1–3; PDN 60 mg/m² days 1–21</td>
<td>1</td>
<td>CNS relapse</td>
</tr>
<tr>
<td>3</td>
<td>CAM+ intrathecal injection</td>
<td>CTX 750 mg/m² days 1, 8; Ara-C 100 mg/m² days 1–3, 8–10; 6-MP 60 mg/m² days 1–7</td>
<td>1</td>
<td>PR</td>
</tr>
<tr>
<td>4</td>
<td>HD-MTX+ intrathecal injection</td>
<td>MTX 3 g/m² day 1</td>
<td>1</td>
<td>CR</td>
</tr>
<tr>
<td>5</td>
<td>Hyper B+ intrathecal injection</td>
<td>MTX 1.0 g/m² day 1; Ara-C 2 g/m² days 2–3 Q12H; methylprednisolone 30 mg/m² days 1–3</td>
<td>1</td>
<td>CR</td>
</tr>
<tr>
<td>6</td>
<td>HD-MTX intrathecal injection</td>
<td>MTX 3 g/m² day 1</td>
<td>1</td>
<td>CR</td>
</tr>
</tbody>
</table>

**Abbreviations:** 6-MP, 6-mercaptopurine; Ara-C, cytarabine; CAM+, cyclophosphamide, cytarabine, 6-mercaptopurine plus; CNS, central nervous system; CR, complete remission; CTX, cyclophosphamide; DNR, daunorubicin; HD-MTX, high-dose methotrexate; Hyper B+, methotrexate, cytarabine, methylprednisolone plus; MTX, methotrexate; PDN, prednisone; PR, partial remission; Q12H, every 12 hours; VDCP, vindesine, daunorubicin, cyclophosphamide, prednisone; VDS, vindesine.
Unfortunately, after 2-month therapy of oral chidamide, recurrent skin lesions and bone marrow blasts appeared. The patient relapsed and finally succumbed to the disease 17 months after the initial onset of lymphadenopathy.

**Discussion**

BPDCN is extremely rare, and its clinical presentation is often ambiguous and confusing. The atypical immunophenotype also adds difficulty to the precise diagnosis. There is no consensus on the optimal therapeutic strategy for BPDCN. It is highly responsive to chemotherapy used for ALL, acute myeloid leukemia (AML) and non-Hodgkin lymphoma, but the median event-free survival is only 10 months. Some patients received long-term survival after allo-SCT, especially children, but there were still 30%-40% of them who experienced relapse even after performing allo-SCT. Hence, the understanding of the pathobiology of BPDCN and the development of novel agents is urgently demanded.

There are very few clinical studies on novel agents about BPDCN. Frankel et al reported the first prospective study on the treatment of BPDCN, in which 11 patients were treated with a single course of SL-401 at 12.5 μg/kg intravenously over 15 minutes daily for up to five doses. Seven of nine evaluable (78%) BPDCN patients had major responses, including five complete responses and two partial responses after a single course of SL-401. The median duration of response (DOR) was 5 months (range, 1–20+ months). Montero et al reported the use of venetoclax, a kind of BCL-2 inhibitor, in two patients with relapsed/refractory BPDCN. Both of them received a daily dose escalation of venetoclax of 50 mg, 100 mg and 200 mg to a final dose of 400 mg daily, and the significant decrease in tumor burden was observed at the fourth weeks. Gemcitabine, a well-known nucleoside analog, was found to be effective in an 80-year-old patient with BPDCN. Ulrickson et al reported three patients with relapsed BPDCN who received the gemcitabine/docetaxel regimen (gemcitabine 800 mg/m² days 1 and 8 and docetaxel 75 mg/m² day 8 every 3 weeks); the median overall survival (OS) was 13.3 months (range 8–17 months) with one patient remaining alive and in remission 15 months after treatment. Bétrian et al reported five patients treated with bendamustine hydrochloride, a well-tolerated bifunctional drug acting as an alkylating and antimetabolite agent. Among the four patients evaluable for response, two failed therapy, one died from tumor lysis syndrome after rapid blast clearance from blood and one reached and maintained CR for 7 months, suggesting that bendamustine should be further evaluated in BPDCN.

Chidamide, the first listed benzamide class of HDACi in the world, is currently undergoing global clinical trials for solid tumor treatments. Numerous studies reveal that chidamide exerts a well-characterized anticancer property in a wide range of hematological malignancies, for example, lymphoma, myeloma, AML and ALL. Chidamide and therapeutic chemotherapy have a cooperative effect of inducing apoptosis by DNA damage accumulation and repair defects in AML stem and progenitor cells. The mechanism is similar to the synergistic effect of chidamide and low-dose decitabine in ALL. At the same time, BPDCN has already been classified under myeloid neoplasms, and chemotherapy regimens for both ALL and AML are efficient in BPDCN. In addition, accounting for the demand of the patient to be treated with oral, well-tolerated, effective anticancer medicine, chidamide was chosen for maintenance therapy. Since chidamide at 30 mg biw has been proved to be perfectly effective and well tolerated in recurrent or refractory PTCL, it was given at 30 mg biw, and the actual side effects were really controllable.

However, the patient soon relapsed and the effect of maintenance therapy was not ideal. Chidamide has been proved to be efficient in acute leukemia when combined with other regimens; hence, chidamide in combination with chemotherapy may be a better therapeutic choice. The patient passed away 17 months after the diagnosis, which was much longer than median OS reported by previous studies about BPDCN and any of the novel agents reported before.

**Conclusion**

Here, we report the first case of BPDCN receiving chidamide as maintenance therapy and review clinical studies on the use of novel agents in BPDCN, suggesting that novel agents (SL-401, venetoclax, gemcitabine, docetaxel) can control symptoms and improve DOR and OS. Apart from imaging examination, cerebrospinal fluid should be investigated at diagnosis to identify whether the CNS involvement exists or not and prophylactic intrathecal therapy should be given at the very beginning to prevent the CNS involvement. Chidamide monotherapy in BPDCN demands further investigation, and patients may benefit more when chidamide is used in combination with other regimens. Combination of novel agents with chemotherapy may be the focus of future research on BPDCN.

**Acknowledgment**

This study was supported by the Science and Technology Agency of Jilin province, the study on the diversity and
specificity of lymphoma-associated genes and the individualized treatment of lymphoma (Bethune subject; No 20160101010JC).

Disclosure
The authors report no conflicts of interest in this work.

References